Rybelsus 7mg tablet contains active components such as Semaglutide. This medication belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This medication treats type 2 diabetes by lowering blood sugar levels and promoting weight loss. It also reduces the risk of cardiovascular events in high-risk diabetes patients. It can be combined with other diabetes medications for better control and may lower blood pressure, benefitting cardiovascular health. Additionally, it shows potential in protecting kidneys and slowing diabetic kidney disease progression.

You should not take Rybelsus 7mg tablet if you have a known hypersensitivity to this medication or any of its components. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take this medication. It is not approved for use in pediatric patients with type 2 diabetes. It should not used in individuals with a history of severe gastrointestinal disease, such as gastroparesis. This medication is not recommended for individuals with severe renal impairment or end-stage renal disease.